Trump Imposes 200 Percent Tariff on Indian Generic Drug Exports After Two Years

Trump announced a new import tariff schedule covering roughly 600 generic medicines, starting at zero percent on August 1, 2026 and rising to 200 percent two years later, targeting foreign producers.

India faces potential loss of roughly $9.7 billion in annual generic drug exports to the United States, according to trade analysts, as the steep tariff makes U.S. prices unsustainable and raises fears of retaliatory trade steps.

Indian pharmaceutical industry groups warn the measure will push the sector past its 2030 sales target, citing combined tariff pressure and ongoing shipping challenges that already strain supply chains and could cut projected growth by up to 15 percent.

U.S. officials say the tariff aims to protect domestic manufacturers and reduce reliance on imported medicines, expecting local producers to fill the gap, though critics argue it could raise drug costs for American patients and limit access to affordable treatments.